Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation.

Abstract	Post-transplant lymphoproliferative disorders (PTLD) represent an heterogeneous group of abnormal lymphoid proliferation related to Epstein-Barr virus (EBV) reactivation that arise early after allogeneic hematopoietic stem cell transplant (HSCT). PLTD with central nervous system (CNS) involvement has been reported in few cases. We describe the case of a 31-year-old-man who developed an EBV-related PTLD with CNS involvement 2 months after an allogeneic unrelated HSCT for acute myeloid leukemia in first complete remission who was successfully treated with rituximab, cidofovir and intrathecal infusion of methotrexate and methylprednisolone.
Authors	C Nozzoli, B Bartolozzi, S Guidi, A Orsi, A M Vannucchi, F Leoni, A Bosi
Journal	Leukemia & lymphoma (Leuk Lymphoma) Vol. 47 Issue 1 Pg. 167-9 (Jan 2006) ISSN: 1042-8194 [Print] United States
PMID	16321845 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Topics	Acute Disease Adult Antineoplastic Combined Chemotherapy Protocols (therapeutic use) Central Nervous System (pathology) Epstein-Barr Virus Infections (complications, pathology) Hematopoietic Stem Cell Transplantation (adverse effects) Humans Leukemia, Myeloid (drug therapy) Lymphoproliferative Disorders (complications, pathology, therapy) Male Remission Induction Transplantation, Homologous Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!